Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000541033 | SCV000659946 | likely benign | RYR1-related disorder | 2024-01-18 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002476208 | SCV000896738 | uncertain significance | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2021-09-14 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001546453 | SCV001765973 | uncertain significance | not provided | 2023-07-20 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Revvity Omics, |
RCV001546453 | SCV003812569 | uncertain significance | not provided | 2019-06-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004024433 | SCV004945835 | uncertain significance | Inborn genetic diseases | 2024-03-08 | criteria provided, single submitter | clinical testing | The c.4847C>T (p.T1616M) alteration is located in exon 33 (coding exon 33) of the RYR1 gene. This alteration results from a C to T substitution at nucleotide position 4847, causing the threonine (T) at amino acid position 1616 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |